

Retraction: multiple articles in volume 56, issue 1 (2019)

Seven research papers and one editorial submitted in response to a call for papers and published in a topic collection on 'Genomic aspects of cancer immunotherapy: Challenges and clinical implications' in the *Journal of Medical Genetics* are retracted¹⁻⁷ by the journal.

WHAT HAPPENED POST-PUBLICATION

The journal investigated possible issues with peer review and editorial assessment of these papers. The articles were investigated together because there was concern about almost all of the content in the collection.

During the peer review and editorial assessment of the work, the guest editors selected the reviewers. The majority of the reviewers and guest editors were at Nanjing University. There was evidence of improbable device use in many articles, and compromised peer review in almost all articles.

The current Editor-in-Chief judges that the collection is out of scope for the journal, and so it will not be rereviewed for publication in the journal.

REASONS FOR RETRACTION

Seven research papers in the collection¹⁻⁷ are retracted because their review process was irreparably compromised. The linked editorial which describes the collection⁸ is also retracted because the vast majority of the research referred to in the editorial is retracted. We did not find evidence that the review process for the case report in the collection was compromised, hence this is not being retracted.⁹

FURTHER ACTION

Nanjing University Hospital, which is listed as an affiliation of several of the individuals involved, will be informed of the reasons for retraction.

© Author(s) (or their employer(s)) 2026. No commercial re-use. See rights and permissions. Published by BMJ Group.

To cite: *J Med Genet* Epub ahead of print: [please include Day Month Year]. doi:10.1136/jmg-2026-56-1-2019ret

REFERENCES

- 1 Wang X, Shen H, He Q, *et al.* Exosomes derived from exhausted CD8+ T cells impaired the anticancer function of normal CD8+ T cells. *J Med Genet* 2019;56:29–31.
- 2 Cheng C, Tang N, Li J, *et al.* Bacteria-free minicircle DNA system to generate integration-free CAR-T cells. *J Med Genet* 2019;56:10–7.
- 3 Wang Y-G, Zheng D-H, Shi M, *et al.* T cell dysfunction in chronic hepatitis B infection and liver cancer: evidence from transcriptome analysis. *J Med Genet* 2019;56:22–8.
- 4 Xia A-L, He Q-F, Wang J-C, *et al.* Applications and advances of CRISPR-Cas9 in cancer immunotherapy. *J Med Genet* 2019;56:4–9.
- 5 Chen D, Chen W, Xu Y, *et al.* Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target. *J Med Genet* 2019;56:43–9.
- 6 Wang X, He Q, Shen H, *et al.* Genetic and phenotypic difference in CD8+ T cell exhaustion between chronic hepatitis B infection and hepatocellular carcinoma. *J Med Genet* 2019;56:18–21.
- 7 Weng Q, Chen M, Li M, *et al.* Global microarray profiling identified hsa_circ_0064428 as a potential immune-associated prognosis biomarker for hepatocellular carcinoma. *J Med Genet* 2019;56:32–8.
- 8 Xia AL, Xu Y, Lu XJ. Cancer immunotherapy: challenges and clinical applications. *J Med Genet* 2019;56:1–3.
- 9 Al-Samkari H, Snyder GD, Nikiforow S, *et al.* Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the *PRF1A91V* gene polymorphism. *J Med Genet* 2019;56:39–42.